PLX Projected Dividend Yield
Protalix BioTherapeutics Inc ( AMEX : PLX )Protalix BioTherapeutics, Inc. is a biopharmaceutical company. Co. is focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx. In addition, the Co. is developing PEGylated uricase, or PRX-115, for the treatment of severe gout, Long Acting (LA) DNase I, or PRX-119, for the treatment of NETs-related diseases, and other technologies and preclinical assets. Its product, Elelyso is an enzyme replacement therapy (ERT) for the treatment of patients with Gaucher disease. 21 YEAR PERFORMANCE RESULTS |
PLX Dividend History Detail PLX Dividend News PLX Competitors News |
Year |
Declaration Date |
Ex-Dividend Date |
Record Date |
Payable Date |
Dividend $ Amount |
Total: |
0.0000 |